Newstin ORGANIZING THE NEWS

THIS WEEK'S PICKS

in all

New to Newstin? Take a look at what we are doing...

* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Full Coverage

Santhera Receives First Product Approval: Health Canada Approves Catena® for Treatment of...

ad-hoc-news.de

Jul 24, 2008

Story Timeline: 75 days

Santhera Receives First Product Approval: Health Canada Approves Catena® for Treatment of Friedreich's Ataxia Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceuticalcompany focused on neuromuscular diseases, announced today thatHealth Canada has approved with conditions SNT-MC17/idebenone for thetreatment of Friedreich's Ataxia. Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceuticalcompany focused on neuromuscular diseases, announced today thatHealth Canada has approved with conditions SNT-MC17/idebenone for thetreatment of Friedreich's Ataxia. Health Canada's decision is thefirst marketing authorization worldwide for any Friedreich's Ataxiatherapy. The new drug will be marketed in Canada under the brand nameCatena®. Santhera has established a wholly owned Canadian subsidiary,Santhera... [read full story]

Add Comment